Literature DB >> 26291798

Are FSHR polymorphisms risk factors to premature ovarian insufficiency?

Emerson Barchi Cordts1, Monise Castro Santos1, Bianca Bianco1, Caio Parente Barbosa1, Denise Maria Christofolini1.   

Abstract

Premature ovarian insufficiency (POI) is an ovarian dysfunction characterized by increased FSH levels and amenorrhea before 40 years old. In recent years, the search for genetic causes of POI intensified and studies have been published relating the presence of mutations and polymorphisms in genes associated with development, recruitment and oocyte atresia. The aim of this study was to evaluate the presence of FSHR polymorphisms in our population and contribute with the elucidation of POI etiology. To achieve it, we have studied 100 patients with POI (G1), 60 patients with border line levels of FSH (G2) and 123 controls with regular menopause onset. Cytogenetic analysis of patients' samples and genotyping of Asn680Ser and Ala307Thr polymorphisms were performed in cases and controls. Cytogenetic analysis showed that 92% of G1 patients had normal karyotype, 4% presented polymorphic variants, 3% presented mosaic karyotype involving X chromosome. In G2, 91.6% had normal karyotype results, 3.2% displayed polymorphic variants, and 3.3% presented a mosaic karyotype involving X chromosome. Statistical comparison showed that the polymorphic allele of Ala307Thr polymorphism is more frequent in patients than in controls (G1: p < 0.001 and G2: p = 0.0259). This association has not been previously reported. We concluded that Ala307Thr polymorphism in FSHR can be potentially associated to POI development and can be considered as a screening marker in patients with ovarian failure signals.

Entities:  

Keywords:  FSHR; Follicle stimulating hormone; X chromosome; infertility; premature ovarian insufficiency

Mesh:

Substances:

Year:  2015        PMID: 26291798     DOI: 10.3109/09513590.2015.1032933

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  7 in total

1.  "Evaluation of four genes associated with primary ovarian insufficiency in a cohort of Mexican women".

Authors:  K J Juárez-Rendón; J E García-Ortiz
Journal:  J Assist Reprod Genet       Date:  2018-06-18       Impact factor: 3.412

Review 2.  Primary ovarian insufficiency in classic galactosemia: current understanding and future research opportunities.

Authors:  Mili Thakur; Gerald Feldman; Elizabeth E Puscheck
Journal:  J Assist Reprod Genet       Date:  2017-09-20       Impact factor: 3.412

Review 3.  Mechanistic insight into how gonadotropin hormone receptor complexes direct signaling†.

Authors:  Gillian P Johnson; Kim Carol Jonas
Journal:  Biol Reprod       Date:  2020-04-15       Impact factor: 4.285

4.  Recent developments in genetics and medically-assisted reproduction: from research to clinical applications†‡.

Authors:  J C Harper; K Aittomäki; P Borry; M C Cornel; G de Wert; W Dondorp; J Geraedts; L Gianaroli; K Ketterson; I Liebaers; K Lundin; H Mertes; M Morris; G Pennings; K Sermon; C Spits; S Soini; A P A van Montfoort; A Veiga; J R Vermeesch; S Viville; M Macek
Journal:  Hum Reprod Open       Date:  2017-12-04

5.  ABO blood type is associated with ovarian reserve in Chinese women with subfertility.

Authors:  Liangshan Mu; Wumin Jin; Haiyan Yang; Xia Chen; Jiexue Pan; Jia Lin; Peiyu Wang; Xuefeng Huang
Journal:  Oncotarget       Date:  2016-08-09

Review 6.  Recent developments in genetics and medically assisted reproduction: from research to clinical applications.

Authors:  J C Harper; K Aittomäki; P Borry; M C Cornel; G de Wert; W Dondorp; J Geraedts; L Gianaroli; K Ketterson; I Liebaers; K Lundin; H Mertes; M Morris; G Pennings; K Sermon; C Spits; S Soini; A P A van Montfoort; A Veiga; J R Vermeesch; S Viville; M Macek
Journal:  Eur J Hum Genet       Date:  2017-12-04       Impact factor: 4.246

7.  RANKL is a new Epigenetic Biomarker for the Vasomotor Symptom During Menopause.

Authors:  R Kalkan; M Altarda; O Tosun
Journal:  Balkan J Med Genet       Date:  2020-08-26       Impact factor: 0.519

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.